

# CURRICULUM – VITAE

## Dr. Sudhir Bhandari



MBBS (TRIPLE GOLD MEDALIST)  
MD, FRCP (LONDON), FACP, FACE  
DNB, MNAMS, FICP, AFICA (USA), FISC, FRSSDI  
FELLOW OF DIABETES INDIA (FDI)  
Consultant Physician & Diabetologist  
Sr. Professor of Medicine  
S.M.S. Medical College & Hospital, Jaipur  
Honorary Physician to H. E. Governor of Rajasthan  
Advisor & Member Board of Management, Jaipur National University Institute of Medical Sciences  
Associate Editor International Journal of Diabetes in Developing Countries

### **Mailing Address:**

D-126/A, Krishna Marg,  
University Road, Bapu Nagar,  
Jaipur - 302015  
Ph.: 0141-27102324, 2710434  
Fax. : +91-141-2719119  
M : +91-98290-78844  
E-mail: drs\_bhandari@yahoo.com  
dr.bhandaricr@gmail.com

### **1. PRESENT POSITION**

- **SR. PROFESSOR IN UPGRADED DEPT OF MEDICINE & ENDOCRINE SERVICES**
- **CONSULTANT IN INTERNAL MEDICINE, DIABETOLOGY , METABOLIC & ENDOCRINE PHYSICIAN SMS Medical College & Hospital, Jaipur**
- **HON. PHYSICIAN TO H.E. THE GOVERNOR OF RAJASTHAN**
- MEMBER BOARD OF MANAGEMENT (GOVERNOR'S NOMINEE) IN UNIVERSITY OF HEALTH SCIENCES
- MEMBER BOARD OF MANAGEMENT JAIPUR NATIONAL UNIVERSITY & FORTHCOMING JNU INSTITUTION OF MEDICAL SCIENCES

### **2. ACADEMIC EXPERIENCE**

- SR. PROFESSOR of Medicine in upgraded Department of Medicine & endocrine services SMS Medical College. 27 years of teaching experience since 1987.
- In charge of Undergraduate & Post Graduate Teaching Programme Internal Medicine & Endocrinology.
- Examiner of MBBS & BDS exam.
- Guide for postgraduate students for degree of MD/DNB.
- Published many papers in National & International Journals.

### **3. Clinical Experience**

1. Handling all Internal Medicine & Endocrine Diseases- Pituitary, Thyroid, Adrenal, Diabetes- Type-1, Type-2, Osteoporosis, Obesity, Growth Retardation & many others in OPD & IPD.
2. Consulting all endocrine references from various departments like, Gynaecology, Surgery, Neurosurgery, Orthopedics, Ophthalmology, ICU & ICCU.
3. Post graduate & undergraduate teaching of endocrinology subjects for 27 years.

#### 4. Publications & Papers

S.No	Name of Article	Author Name	Journal Name	Year	Type of Journal
1	To evaluate is elevated serum triglyceride the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes. Volume-6   Issue-9   September-2017   ISSN No 2277 - 8179   IF : 4.176   IC Value : 78.46	Dr.Sudhir Bhandari Dr.Dilip Nagarwal Dr Barkha Goyal, Dr Jaswant Goyal*, Dr. Purva Sharma,	INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH	2017	INTERNATIONAL
2	To determine the difference in mean serum CPK level in H1N1 Positive and H1N1 Negative influenza like illness cases, SMS Hospital, Jaipur.  <i>Volume 12, Issue 5 Ver. 1 (Sep. – Oct. 2017), PP 26-30</i>	Dr. Sudhir Bandhari, Dr. Madan, Dr Barkha Goyal, Dr Jaswant Goyal*, Dr. Purva Sharma, Dr. Pragya Sharma	<i>IOSR JOURNAL OF PHARMACY AND BIOLOGICAL SCIENCES (IOSR-JPBS)</i>	2017	National
3	ULTRASONOGRAPHIC EVALUATION OF GALLBLADDER VOLUME IN TYPE 2 DIABETICS AND ITS CORRELATION WITH AUTONOMIC NEUROPATHY Abstract #1106	Dr Sudhir Bhandari Dr Banshi Saboo Dr Suresh Yadav Dr Barkha Goyal Dr Jaswant Goyal	AACE-2017, LATE BREAKING ABSTRACT	2017	International
4	EFFECTS OF SAROGLITAZAR ON GLYCEMIC LIPID PARAMETERS IN TYPE 2 DIABETES PATIENTS ABSTRACT #1105	Dr Sudhir Bhandari <sup>1</sup> , Dr Kushan Sengupta <sup>1</sup> , Dr Jaswant Goyal <sup>2</sup> , Dr Barkha Goyal <sup>2</sup> , Dr Banshi Saboo <sup>3</sup>	ABSTRACTS – LATE BREAKING	2017	International
5	To study the association between plasma homocysteine and microvascular and macrovascular complications in type 1 Diabetes Mellitus. Volume-6   Issue-9   September-2017   ISSN No 2277 - 8179   IF : 4.176   IC Value : 78.46	Dr Sudhir Bhandari Dr Prahlad Dhakar Dr Jaswant Goyal Dr Barkha Goyal Dr Purva Sharma	INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH	2017	INTERNATIONAL
6	Avascular necrosis of bone with hemiparesis: a rare	Dr Sudhir	INTERNATIONAL JOURNAL OF	2017	International

	presentation of primary antiphospholipid antibody syndrome  May-June 2017   Vol 4   Issue 3 Page 850	Bhandari1, Dr Vishal Gupta, Dr Kushan Sengupta, Dr Jaswant Goyal2, Dr Uttam Kumar3	ADVANCES IN MEDICINE		
7	Correlation of hyperuricemia with microalbuminuria in patients with type 2 diabetes mellitus in relation to glycemic control  <i>Volume 3, Issue 4 (Jul. – Aug. 2017), PP 37-43</i>	Dr Barkha Goyal1, Dr Jaswant Goyal*2, Dr Maheep Sinha3, Dr Bushra Fiza4, Dr. Purva Sharma5, Dr. Sudhir Bandhari6, Dr. Pragya Sharma7,	<i>IOSR JOURNAL OF BIOTECHNOLOGY AND BIOCHEMISTRY (IOSR-JBB)</i>	2017	National
8	RATIONALITY OF THE FIXED DOSE COMBINATION OF TELMISARTAN AND AMLODIPINE IN MANAGEMENT OF MILD TO MODERATE HYPERTENSION UNRESPONSIVE TO LOW DOSE MONOTHERAPY Volume 6, Issue 9, 893-905.	Prof. Jaswant Goyal1, Dr Barkha Goyal*2, Dr Purva Sharma3 and Dr Sudhir Bhandari	WORLD JOURNAL OF PHARMACEUTICAL RESEARCH	2017	International
9	Association of glycosylated hemoglobin with microalbuminuria in patients with type 2 diabetes mellitus  Volume 13, Number 4 (2017) pp. 311-323	Dr. Barkha Goyal, Dr. Jaswant Goyal Dr Sonali Sharma Dr. Purva Sharma, Dr. Sudhir Bandhari Dr. Pragya Sharma	INTERNATIONAL JOURNAL OF BIOTECHNOLOGY AND BIOCHEMISTRY	2017	National
10	Interstitial lung disease – A rare diagnosis in HIV 4 3 – 4 5	Dr Sudhir Bhandari	INDIAN JOURNAL OF MEDICAL SPECIALITIES	2016	National
11	Intracranial hydatid cyst – A rare manifestation of Echinococcus infestation <a href="#">Volume 6, Issue 4</a> , October–December 2015, Pages 170–172	Dr Sudhir Bhandaria, Dr C.L. Navalb, Dr Vishal Gupta, Dr Sandeep Jainb, Dr Suresh Yadavb	INDIAN JOURNAL OF MEDICAL SPECIALITIES	2015	National
12	Profiling the Mortality due to Influenza A (H1N1) pdm09 at a Tertiary Care Hospital in	Raman Sharma1, Sujata Agarwal2, Sudhir Mehta1, CL Nawal1,	JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA	2015	National

	Jaipur during the Current Season - January & February Vol. 63 ■ April 2015	Sudhir Bhandari <sup>3</sup> , Monika Rathore <sup>4</sup> , Abhishek Agarwal <sup>5</sup>			
13	Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone 2014 Jul;30(7):1257-66. doi: 10.1185/03007995.2014.909393. Epub 2014 May 2.	Pareek A1, Chandurkar N, Thomas N, Viswanathan V, Deshpande A, Gupta OP, Shah A, Kakrani A, Bhandari S, Thulasidharan NK, Saboo B, Devaramani S, Vijaykumar NB, Sharma S, Agrawal N, Mahesh M, Kothari K	CURRENT MEDICAL RESEARCH & OPINION	2014	National
14	Rectus sheath haematoma: a rare presentation of non-contact strenuous Exercises Br J Sports Med 2007;41:688–690. doi: 10.1136/bjism.2007.036087	Dr Sudhir Bhandari	BRITISH MEDICAL JOURNAL	2007	International
15	GUARD Study: Effectiveness and Safety of Vildagliptin and Vildagliptin - Metformin Combination in Indian patients with Type 2 Diabetes Mellitus	Dr Sudhir Bhandari		2014	National
16	Relative status of conventional and newer insulin	Dr Sudhir Bhandari	RAJASTHAN MEDICAL JOURNAL	1988	National
17	Pregnancy & Diabetes	Dr Sudhir Bhandari	S.D.M.H. JOURNAL	1995	National
18	Management of Diabetic patient during surgery	Dr Sudhir Bhandari	S.D.M.H. JOURNAL	1995	National
19	Exercise in the management of Diabetes Mellitus	Dr Sudhir Bhandari	S.D.M.H. JOURNAL	1995	National
20	Digital Subtraction Angiography	Dr Sudhir Bhandari	S.D.M.H. JOURNAL	1995	National
21	Glanzmann's Thrombasthenia – A Case Report	Dr Sudhir Bhandari			National
22	A Study of lipid profile in ischaemic heart disease	Dr Sudhir Bhandari	S.D.M.H. JOURNAL	1989	National
23	AIDS: A warning for travellers	Dr Sudhir Bhandari	S.D.M.H. JOURNAL	1989	National

24	Prednisolone in Guillain Barre Syndrome – A Clinical Study	Dr Sudhir Bhandari	S.D.M.H. JOURNAL	1989	National
25	Bone Marrow Transplantation	Dr Sudhir Bhandari	RAJASTHAN MEDICAL JOURNAL	1990	National

##### 5. Orations –Presentations in Conferences/Symposia

S.N.	Topic	Conference	Date/Year
1	Management of Headache	<b>API- DIAS-2017</b>	12-11-2017
2	<b>PLENARY SESSION 4</b> <b>SESSION CHAIRMAN:-</b> Neuroscience research in Disability/Early Intervention for Childhood disorders	<b>NATIONAL CONFERENCE ON DISABILITY: MULTIPLE POSSIBILITIES AND PROSPECTS</b> (Ability Continuum , Diversity, Access and Inclusion) 10-11 <sup>th</sup> Nov-2017, Hotel Clarks Amer, Jaipur	10-11 <sup>th</sup> Nov-2017,
3	Diabetes , Muscles & Bone Diseases	Chairing The Session of <b>RSSDI 2017</b> , Bhubaneswar	3 <sup>rd</sup> to 5 <sup>th</sup> Nov, 2017
4	All about SGLT2 inhibitors, what is new	RSSDI-Diabetes Update-2017	1-10-2017
5	GLOBAL ACADEMIA Presents	CME by Lilly	27-9-2017
6	GLP1-RA Therapy: Are all same?	CME BY SANOFI INDIA	20-8-2017
7	Psycho-sociology of Diabetes	API- DIAS-2017	20-8-2017
8	Evidence based t2dm management	CME BY NOVARTIS	16-8-2017
9	Novel role of Hydroxychloroquin in type 2 Diabetes	ACP-2017( India Chapter)	12-8-2017
10	THE FULL PICTURE OF CV SAFETY WITH GLIPTINS: CLINICAL TRIALS AND BEYOND	CME by Novartis	22-6-2017
11	Predict -Cardiovascular Outcomes of OADs – Tolerability and Benefits with special reference to Glimepiride	CME by Sanofi	17-5-2017
12	SGLT2 INHIBITORS FOCUS ON DAPAGLIFLOZIN	CME BY Astra Zenica	6-5-2017

S.N.	Topic	Conference	Date/Year
13	"INFLAMMATION & DIABETES-THE LINK" (HYDROXYCHLOROQUINE)	RSSDI-Gujarat 2017	30-4-2017
14	SGLT-2 INHIBITORS- BEYOND THE GLYCEMIC CONTROL	Raj RSSDI 2017	26-3-2017
15	DO WE HAVE ENOUGH EVIDENCES TO USE IN PREGNANCY ?-SU	DIPSI 2017	24-3-2017
16	IN-PATIENT MANAGEMENT OF DIABETES	CME BY SANOFI	15-3-2017
17	INCRETIN BASED THERAPY OF TYPE 2 DIABETES MELLITUS	CME BY LILLY	3-3-2017
18	GLYCEMIC VARIABILITY AND THE ROLE OF VOGLIBOSE IN MANAGEMENT OF GV	DIABETESINDIA2017	23- 26 February, 2017
19	TECHNICAL SESSION XII- PHARMOCOGENOMICS OF ANTIDIABETICS	1 <sup>ST</sup> ANNUAL CONFERENCE & SYMPOSIUM ON GENOMICS OF HORMONE & METABOLIC DISORDERS	3 <sup>RD</sup> AND 5 <sup>TH</sup> FEBRUARY 2017
20	DIABETES AND DYSLIPIDEMIA: WHERE DO WE STAND?	CME	9-2-2017
21	WHAT DOES NUMBER MEAN IN MEDICAL PRACTICE	APICON 2017	26-1-2017
22	OPTIMIZING INSULIN INITIATION WORKSHOP	LILLY MEETING HYDERABAD	22-1-2017
23	LOOKING BEYOND GLYCEMIC CONTROL: SGLT-2 INHIBITORS	RAGUDEEP EYE HOSPITAL	12/17/2016
24	<b>NEWER ADVANCES IN MANAGEMENT OF OBESITY</b>	DIACON 2016	3-12-2016
25	<b>HEALTHY LIFESTYLE TO ACHIEVE BETTER QOL IN DIABETES</b>	RSSDI 2016	19-11-2016
26	<b>EMPAGLIFLOZIN: A Next Generation SGLT2 Inhibitor?</b>	CME By Boehringer	18-10-2016
27	All about insulin therapy and clinical evidence on early insulinisation and biosimilar glargine	CME BY Wockhardt	7t Oct 2016
28	SglT2 inhibitors focus on dapagliflozin	CME BY Astrazeneca	30 <sup>th</sup> Sep 2016
29	Evidence based t2dm management	CME BY Novartis	16 <sup>th</sup> Sep 2016

S.N.	Topic	Conference	Date/Year
30	Basal initiation and knowledge sharing (links) insulin initiation and optimization strategies with basal insulins	CME BY SANOFI	2 <sup>nd</sup> Sep 2016
31	SglT2 inhibitors focus on canagliflozin	CME BY JOHNSON AND JOHNSON	31 <sup>st</sup> Aug 2016
32	DUAL PPAR ALPHA / GAMMA AGONIST - ROLE IN NASH & DIABETES	<b>American Diabetes Association ADA- PAMS</b>	27 Aug 2016
33	Prolonging Beta cell survival in T2DM: Mirage or reality?	An Academic initiative by LAI (Lipid Association of India) Inner circle meet	13 Aug 2016
34	Chairperson & Keynote address “Non HDL Cholesterol”	Cardio Diabetic Galaxy Summit by Sun Pharma	12 Aug 2016
35	Evidence Based T2DM Management	CME BY NOVARTIS	25 <sup>th</sup> June 2016
36	The Role of DPP4 Inhibitor in Type-2 Diabetes are All Gliptins Worry-Free?	CME BY NOVARTIS	23 <sup>th</sup> April 2016
37	“D Dimer: Where to send and how to interpret”	APICON 2016	28 <sup>th</sup> January 2016
38	HYDROXYCHLOROQUINE NEW THERAPY IN TYPE II DIABETES MELLITUS	IDSI-2016 (International Symposium on Diabetes)	10-1-2016
39	Hypertension in metabolic syndrome & it's management	Endocrine Update: Seminar on Adiposopathy	10 <sup>th</sup> & 11 <sup>th</sup> Oct 2015
40	Insulin Therapy In Diabetes: When & Why Which & How Can We Ever Overcome Clinical Practice Barriers?	Raj APICON	2015
41	What do we know about Diabetic Kidney Disease from outcome trials	ADA (American Diabetes Association) – EASD Combined Sessions	2015
42	Pitfalls of hypoglycemia: Growing concern in today’s clinical Practice	ADA (American Diabetes Association) – EASD Combined Sessions	2015
43	To Assess the effect of 4mg Saroglitazar on patients of Diabetes Dyslipidemia with Nonalcoholic Fatty Liver Disease for 24 weeks at Diabetes Care Centre	ADA (American Diabetes Association)	2015

S.N.	Topic	Conference	Date/Year
44	Insulin Resistance, dyslipidemia and PPAR: Indian Perspective	APICON	2015
45	Independent Predictors of Erectile Dysfunction (ED) in type 2 Diabetes Mellitus	AACE (American Association of Clinical Endocrinologists)	2015
46	Metabolic Abnormalities in Patients treated with Antiretroviral Therapy	AACE (American Association of Clinical Endocrinologists)	2015
47	Prevalence of Growth Hormone Deficiency in type 1 Diabetes Mellitus Patients at a Tertiary Care Centre in India	AACE (American Association of Clinical Endocrinologists)	2015
48	Analyzing Endothelial Dysfunction in type 2 Diabetes Mellitus Patients Using Flow Mediated Dilatation Score	AACE (American Association of Clinical Endocrinologists)	2015
49	9 Month Safety and Efficacy of Saroglitazar in Diabetic Dyslipidemia	AACE (American Association of Clinical Endocrinologists)	2015
50	Obesity and Insulin Resistance	All India Association for Advancing Research in Obesity	2014
51	Correlation of metabolic syndrome with IHD (based on ct angiography of Coronary vessels) in type 2 diabetes mellitus	AACE (American Association of Clinical Endocrinologists)	2014
52	Association of serum insulin and urinary albumin with occult cad in type 2 Diabetes	AACE (American Association of Clinical Endocrinologists)	2014
53	Acute bulbar palsy a rare manifestation of Thyrotoxicosis	AACE (American Association of Clinical Endocrinologists)	2014
54	To study the association between plasma Homocysteine and microvascular and macrovascular complications in type-1 diabetes mellitus	AACE (American Association of Clinical Endocrinologists)	2014
55	GUARD Study: Effectiveness and Safety of Vildagliptin and Vildagliptin Metformin Combination in Indian patients with Type 2 Diabetes Mellitus	EASD (European Association for the Study of Diabetes)	2014
56	Chromium & Diabetes	Research society for the Study of diabetes in India	2014
57	Perioperative Management of Hypertension	BPCON	2014
58	How aggressive we should be advocating SMBG and for whom?	Diabetes India, Srinagar	2014
59	Targeting Insulin Resistance: Focus on Trivalent Chromium	Research society for the Study of diabetes in India	2014
60	Era of Individualizing of Diabetes Management-Have Incretins paved the way!	Novartis symposia on gliptins New Delhi	2013



S.N.	Topic	Conference	Date/Year
61	To study the association between plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes mellitus	AACE (American Association of Clinical Endocrinologists)	2013
62	Gliptins – Safety, Tolerability & Quality of Life	Diabetes India, Kochi	2013
63	Pathophysiology of Diabetes	Diabetes India, Kochi	2013
64	Right to good health- does poverty stand in the way?	APICON	2013
65	Association of serum insulin and micro albuminuria with occult coronary artery disease in type 2 diabetes patients in North India	IDF (International Diabetes Federation)	2013
66	Diabetic Dyslipidemia & Its Management	Ranbaxy lipid update at Jaipur	2013
67	Is Type 2 DM a really CAD equivalent? How to assess CV risk in Type 2 DM	Research society for the Study of diabetes in India	2012
68	Diabetes management – from drift to paradigm shift	RSSDI Rajasthan Chapter	2012
69	Incretin therapies	Novartis symposia on diabetic management at Coimbatore	2012
70	Incretin Based Therapy of Type 2 Diabetes Mellitus	Lillys CMS on diabetes at Jaipur	2012
71	Self-monitoring of blood glucose (SMBG) in type 2 diabetes	MSD Symposia on diabetes at Udaipur	2011
72	Cardio Friendly Antidiabetics; Need of The Hour	Zydus Cadila cardio diabetic update at Lonawala	2011
73	Drugs to treatment in diabetic SEXUAL DYSFUNCTION	Raj Apicon	2011
74	Update on gliptins : what is new?	RSSDI Rajasthan chapter	2011
75	Beta Blockers: Not for Non-Co-morbid Hypertension with Diabetes	Hypertension summit at Delhi	2006
76	Obesity, Depression and Chronic Mental Illness	APICON (The Association of Physicians of India)	2006
77	Basal Bolus: The Strategy for Managing All Diabetes	Novo Nodisk diabetes update	2006

S.N.	Topic	Conference	Date/Year
78	The Role of DPP4 Inhibitor in Type-2 Diabetes	APICON (The Association of Physicians of India)	2007
79	Intensive insulin therapy	Novo Nodisk diabetes update	2005
80	CCA-IMT (Carotid intima media thickness) In type-2 diabetes to predict future IHD. Its co relation with CTMT and coronary Angio graphic	Raj Apicon at Chitorgardh	2005 Won Dr M. Chenna Reddy Award & Gold Medal for Best scientific Paper
81	Recent advances in management of diabetes	Raj Apicon	2004
82	CCA-IMT (Carotid intima media thickness) In type-2 diabetes & its co-relation with retinopathy and nephropathy	Raj Apicon at Bikaner	2004 Won Dr M. Chenna Reddy Award & Gold Medal for Best scientific Paper
83	Incidence & Management of Sub clinical hypothyroidism	Raj Apicon at Bikaner	2004
84	Prognostic Significance of Micro albuminuria in diabetics & its Correlation of Various Complication & lipid Profile	APICON (The Association of Physicians of India)	2000
85	Risk factor profile of coronary artery disease: A Pilot study	APICON (The Association of Physicians of India)	2000
86	Obesity And Cancer – Lethal Nexus		
87	Significance of WHR as a marker of impaired glucose tolerance test	APICON (The Association of Physicians of India)	1999
88	Significance of WHR (Waist Hip Ratio) in assessing impending IGTT	Research society for the Study of diabetes in India, Goa	1995
89	Clinical significance of right sided chest leads in inferior M.I.	A.P.I. (Association of Physics of India) Jabalpur	1990
90	Effect of Dilyosxr & Isosorbide dinitrate on pre load & after load reduction in valvular heart disease – a clinical study	A.P.I. (Association of Physics of India) Calcutta	1989

S.N.	Topic	Conference	Date/Year
91	Comparative effort tolerance of compensated valvular heart disease following drug therapy of vasodilators & Calcium channel blockers & beta blockers	A.P.I. (Association of Physics of India) Udaipur	1986
92	Management of Portal hypertension	Indian Society of Gastroenterology	
	Vitamin D Deficiency and Cardiovascular Diseases	APICON (The Association of Physicians of India)	
93	Diabetes and Dyslipidemia: Where Do we stand?		
94	Do we still need Pioglitazone for the treatment of type 2 diabetes?"	Raj Apicon	

#### 6. WRITE UP & TEXT BOOK CHAPTERS

- AUTHOR OF A CHAPTER IN TEST BOOK OF MEDICINE BY API (2015)  
CHAPTER – **INSULIN RESISTANCE, DYSLIIDEMIA AND PPAR: INDIAN PERSPECTIVE**
- AUTHOR OF A CHAPTER IN TEST BOOK OF MEDICINE BY API (2013).  
CHAPTER- **VITAMIN D DEFICIENCY & CARDIO VASCULAR DISEASES.**
- EVIDENCE TO EXPERIENCE (ISSUE 4) FROM WOCKHARDT  
TOPIC – **CHROMIUM DINICOCYSTEINATE IN INSULIN RESISTANCE**
- TEXT BOOK OF RSSDI-2015  
TOPIC – **HOW TO LOSE WEIGHT: INNOVATIONS, IDEAS, AND ALGORITHMS**
- TEXT BOOK OF APICON-2016  
TOPIC – **“D DIMER: WHERE TO SEND AND HOW TO INTERPRET”**
- TEXT BOOK OF DIABETESINDIA-2017  
TOPIC – **“GLYCEMIC VARIABILITY AND THE ROLE OF VOGLIBOSE IN MANAGEMENT OF GV**

#### 7. INVITATION AS FACULTY (SPEAKER)

Regularly invited as FACULTY to give orations at

- **API conferences** (Association of Physician of India)
- **RSSDI** (Research Society for the Study of Diabetes in India)
- **RAJ Apicon**
- **Diabetes India** (World congress of Diabetes)

(Member of Core Group who finalised Indian consensus guidelines of management of type 1 diabetes.)

- **International Cardiometabolic and metabolic symposia** in various countries.

## 8. **MEMBERSHIP OF**

- **API** (Association of Physicians of India)
- **RSSDI** (Research Society for the Study of Diabetes in India)
- **Endocrine society of India (ESI)**
- **Hypertension society of India**
- **CSI** (Cardiological Society of India)
- **AACE** (American Association of Clinical Endocrinologists)
- Organising secretary for **AIAAROCON 2014**
- Indian Podiatry Association.

## 9. **NATIONAL AWARDS**

- **DR. P.J. MEHTA, YOUNG SCIENTIST AWARD IN NEW DELHI**

Dec. 2002 in Hypertension Society of India Conference.

- **DR. CHENNA REDDY GOLD MEDAL**

For best scientific paper in RAJ APICON in Oct. 2002 (CCA-IMT in type 2 M.D.)

- **DR. CHENNA REDDY GOLD MEDAL**

For best scientific paper in RAJ APICON in Oct. 2003 (CCA-IMT caretation with nephropathy/retinopathy in type-2 MD).

- **DR. CHENNA REDDY GOLD MEDAL**

For best scientific paper in RAJ APICON in Oct. 2005 (CCA-IMT Caretation with CAD in type 2 DM).

- **STATE MERIT AWARD BY HON. C.M. ON 15TH AUG. 2002**

For outstanding Medical Professional for research & clinical work.

- **RAJ GAURAV AWARD BY H.E. THE GOVERNOR**

April 2002 for Distinguish Doctor of the state.

- Various felicitations for excellent oration at Clinical updates, Seminars, Lecturers in various social and public programme.

- **TIMES OF INDIA, HEALTH AWARD**

for outstanding Physician – Jul 2013

- **LITERACY HERO AWARD BY ROTARY INTERNATIONAL-2017**

For achieving total literacy for special children (Physical & Mental challenged) in recognition of “SERVICE ABOVE SELF”

**10. CLINICAL RESEARCH EXPERIENCE**

CERTIFIED IN ESSENTIAL GCP BY BROOKWOOD INTERNATIONAL ACADEMY. Following trials are successfully completed:

- Dyslipidemia (Multicenteric double blind study, Phase 3)
- 2 Diabetes (Multicenteric comparatives study, Phase 3)
- Hypertension in Type II patients, phase III trial
- SHINE study: To study the Human insulin initiation pattern in Type II DM patients who are uncontrolled on their current medicines (Dinoo Consultants)
- TEENS Study: Impact of process of medical care on glycemic control & quality of life in Juvenile diabetes.

**11. Ongoing Clinical Trial:**

- VERIFY trial (Vildagliptine Efficacy in combination with Metformin for treatment of T2DM) by Novartis

**12. FOLLOWING PMS TRIAL CONDUCTED IN LAST 5 YEAR**

- ISTART study for Novelet 2005.
- Serited efficacy in Chronic Bronchial Asthma and COPD (2006).
- PREDICTIVE Study for Levemir in 2007.
- IMPROVE for Novomix in 2008.
- Conducted 4 Major Post Marketing trials with Lantus in Type 2 Diabetes patients at my centre - LANTRUS, LAUREL, CREATE, INSUTREAT.
- Sustained release Diltiazem in Hypertension and IHD patients (Modi Mundis).
- Status of Inj. GLARITUS (Glargene) in type 2 Diabetic patient with secondary failure.
- Phase III trials of using Daflon in Peripheral Vascular Disease with help of Doppler study in 2003 (Serdia Pharma).

- Efficacy of Sitagliptin (Januvia) in bringing glycemic control (Hb 1Ac) in more than 100 patients & presented data in an International Meet at Hyderabad.
- Novomix 30 superior PPG control along with effective FPG control.

### 13. **SERVICE TO SOCIETY**

- CONDUCTING VARIOUS CARDIO-DIABETIC-METABOLIC & MEDICAL SPECIALITY CAMPS IN JAIPUR & RURAL AREAS EVERY MONTH FOR LAST 20 YEARS UNDER AUSPICIOUS OF CHARITABLE MARUDHAR MEDICAL TRUST.

#### **A. GSE - Group Study Exchange Program member of Rotary to Cardiff (UK) in April 1986**

#### **B. Activity of Marudhar Medical Trust:**

The Trust is actively engaged in charitable activities, research work and public awareness programmes under Guidance of **DR. SUDHIR BHANDARI**.

On 15th of every month Dr Sudhir Bhandari conducts medical Camp at Jaitaran (Pawan Dham) 280 km From Jaipur. A Team of Ten Staff members assemble and the following test are conducted:

1. ECG
2. BS Examination
3. Bone densitometry
4. Spirometry
5. All Bio chemistry
6. X-ray

Average 400 to 500 Patients come which include Diabetes, Hypertension, Heart problems, Asthma and metabolism syndromes.

There are a large number of geriatric Patients with Osteoarthritis, Backache and COPD.

Once the patient comes He is thoroughly worked up. The Relevant investigations are done and they are given medicines free of cost to a great extent from the trust. All serious patients and critically ill patients are brought to S.M.S Jaipur for further investigation from Trust thus helping the patients financially.

#### **Clinical Research:**

Under auspicious of **Marudhar Medical trust**, We are doing lot of Clinical Research Where Dr. Sudhir Bhandari is the principal investigator, Dr. Sudha Mathur and Dr. Barkha Goyal are co Investigators with 4 Supporting Staff.

#### **C. Medical social Responsibility:**

We conduct public awareness programmes for lifestyle diseases, as mentioned below, almost one program every week:

1. How to stay healthy in spite of having diabetes, hypertension and heart problem.
2. How to stay healthy in the era of fast food.
3. Education programmes in the school about child obesity, junk food and smoking.
4. Education program in corporate office government offices, colleges and Rotary clubs.
5. Organising diabetic education exhibition at various places.

During these programmes Blood Sugar, B.P. monitoring & ECGs are done as complimentary. Lots of reading material is distributed to audience about lifestyle diseases.

The Marudhar Medical Trust is proposing a cardio-diabetes center which will support our charitable activities also.

### **D. Education Programs for school:**

Conducting awareness programs for school children for fitness, healthy eating, swine flu, dengue and seasonal diseases this includes an audio visual program and question answer session with children.